Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Inmune Bio Inc (INMB)

Inmune Bio Inc (INMB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
INmune Bio, Inc. (INMB) Q2 2022 Earnings Call Transcript

INMB earnings call for the period ending June 30, 2022.

INMB : 5.19 (-6.49%)
INmune Bio, Inc. Announces Second Quarter 2022 Results and Provides Business Update

Company to Host Conference Call Today, August 3, at 4:30pm ET...

INMB : 5.19 (-6.49%)
INmune Bio, Inc. to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, August 3

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 27, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc....

INMB : 5.19 (-6.49%)
INmune Bio, Inc. CEO, Raymond J. Tesi, MD, to Participate in Two Upcoming Panels on Alzheimer's Disease

Alzheimer's Association International Conference ("AAIC") – Systems Biology of Alzheimer's Disease Panel on August 4, 2022 Moderated by Jeffrey Cummings,...

INMB : 5.19 (-6.49%)
INmune Bio, Inc. Presents Data on Combination Therapy with INB03™ on Overcoming Resistance to HER2 Targeted Therapies in Breast Cancer

In pre-clinical models of trastuzumab resistant MUC4 HER2+ breast cancer, treatment with INB03™ decreases MUC4 expression, reverses resistance to...

INMB : 5.19 (-6.49%)
INmune Bio, Inc. to Provide Additional Manufacturing Information to FDA as Part of IND Application for XPro1595™ in Alzheimer’s Disease

BOCA RATON, FL., May 23, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on...

INMB : 5.19 (-6.49%)
INmune Bio, Inc. (INMB) Q1 2022 Earnings Call Transcript

INMB earnings call for the period ending March 31, 2022.

INMB : 5.19 (-6.49%)
INmune Bio, Inc. Announces First Quarter 2022 Results and Provides Business Update

Company Dosed First Phase 2 Mild Alzheimer’s Disease Patient with Xpro1595; Presented Data from Ongoing INKmune™ Studies Suggesting Increased NK Cell...

INMB : 5.19 (-6.49%)
INmune Bio, Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on Thursday, May 5

Management to host conference call and webcast at 4:30 pm ET on that day...

INMB : 5.19 (-6.49%)
INmune Bio, Inc. to Participate at the B. Riley Neuro & Ophthalmology Conference

Boca Raton, FL, April 25, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that...

INMB : 5.19 (-6.49%)

Barchart Exclusives

Dividend Aristocrats: The Best of the Best for Stable Income
Dividend Aristocrats' ability to increase their dividends indicates strong earnings and a solid business foundation, which lowers investment risk. Moreover, their consistent earnings growth often enables them to outperform broader market indices. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar